These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22160165)

  • 41. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
    Nachtergael I; Vertongen P; Langer I; Perret J; Robberecht P; Waelbroeck M
    Biochem J; 2003 Mar; 370(Pt 3):1003-9. PubMed ID: 12475394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of vasoactive intestinal peptide (VIP) on scopolamine-induced amnesia in the rat.
    Yamaguchi Y; Kobayashi H
    Neuropeptides; 1994 Mar; 26(3):153-8. PubMed ID: 8208360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
    Tsutsumi M; Claus TH; Liang Y; Li Y; Yang L; Zhu J; Dela Cruz F; Peng X; Chen H; Yung SL; Hamren S; Livingston JN; Pan CQ
    Diabetes; 2002 May; 51(5):1453-60. PubMed ID: 11978642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Behavorial responses to the 5-HT1A receptor antagonist NAN190 injected into rat CA1 hippocampal area.
    Belcheva I; Belcheva S; Petkov VV; Hadjiivanova C; Petkov VD
    Gen Pharmacol; 1997 Mar; 28(3):435-41. PubMed ID: 9068987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autoradiographic analysis of the distribution of vasoactive intestinal peptide binding sites in the vertebrate central nervous system: a phylogenetic study.
    Dietl MM; Hof PR; Martin JL; Magistretti PJ; Palacios JM
    Brain Res; 1990 Jun; 520(1-2):14-26. PubMed ID: 2169952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
    Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
    J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sigma-1 receptor stimulation by dehydroepiandrosterone ameliorates cognitive impairment through activation of CaM kinase II, protein kinase C and extracellular signal-regulated kinase in olfactory bulbectomized mice.
    Moriguchi S; Yamamoto Y; Ikuno T; Fukunaga K
    J Neurochem; 2011 Jun; 117(5):879-91. PubMed ID: 21434925
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CEPO-Fc (An EPO Derivative) Protects Hippocampus Against Aβ-induced Memory Deterioration: A Behavioral and Molecular Study in a Rat Model of Aβ Toxicity.
    Hooshmandi E; Motamedi F; Moosavi M; Katinger H; Zakeri Z; Zaringhalam J; Maghsoudi A; Ghasemi R; Maghsoudi N
    Neuroscience; 2018 Sep; 388():405-417. PubMed ID: 30102955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The stimulatory effect of vasoactive intestinal peptides on the cortisol production of guinea pig Zona fasciculata cells: an extra-ACTH regulatory model of the adrenocortical function.
    Fang VS; Juan CC; Hsu YP; Won JG; Ho LT
    Chin J Physiol; 2001 Jun; 44(2):73-9. PubMed ID: 11530947
    [TBL] [Abstract][Full Text] [Related]  

  • 51. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
    Moody TW; Jensen RT; Fridkin M; Gozes I
    J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components.
    Hodges RR; Zoukhri D; Sergheraert C; Zieske JD; Dartt DA
    Invest Ophthalmol Vis Sci; 1997 Mar; 38(3):610-9. PubMed ID: 9071214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of NAD-299 and TCB-2 on learning and memory, hippocampal BDNF levels and amyloid plaques in Streptozotocin-induced memory deficits in male rats.
    Afshar S; Shahidi S; Rohani AH; Komaki A; Asl SS
    Psychopharmacology (Berl); 2018 Oct; 235(10):2809-2822. PubMed ID: 30027497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration.
    Cui X; Cao DY; Wang ZM; Zheng AP
    Pharmazie; 2013 Jan; 68(1):69-74. PubMed ID: 23444784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Select cognitive deficits in vasoactive intestinal peptide deficient mice.
    Chaudhury D; Loh DH; Dragich JM; Hagopian A; Colwell CS
    BMC Neurosci; 2008 Jul; 9():63. PubMed ID: 18616823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
    Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
    Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.
    Gozes I; Bardea A; Reshef A; Zamostiano R; Zhukovsky S; Rubinraut S; Fridkin M; Brenneman DE
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):427-32. PubMed ID: 8552653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Scopolamine induced memory impairment; possible involvement of NMDA receptor mechanisms of dorsal hippocampus and/or septum.
    Khakpai F; Nasehi M; Haeri-Rohani A; Eidi A; Zarrindast MR
    Behav Brain Res; 2012 May; 231(1):1-10. PubMed ID: 22421366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring.
    Hill JM; Cuasay K; Abebe DT
    Exp Neurol; 2007 Jul; 206(1):101-13. PubMed ID: 17521630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
    Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
    Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.